Last reviewed · How we verify
Aggressive systemic mastocytosis
Approved treatments
- Rydapt · Novartis
Rydapt blocks the activity of the Kit receptor, which is involved in the growth and survival of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Aggressive systemic mastocytosis patent landscape — cliff calendar, originator estates, attackable patents
- Aggressive systemic mastocytosis treatment landscape brief
- Aggressive systemic mastocytosis treatment updates RSS
Frequently asked questions about Aggressive systemic mastocytosis
What drugs treat Aggressive systemic mastocytosis?
Tracked treatments include Rydapt.
What is the treatment for Aggressive systemic mastocytosis?
Standard treatment for Aggressive systemic mastocytosis includes Rydapt. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Aggressive systemic mastocytosis patent cliff · Aggressive systemic mastocytosis CI report
- Treatment: Rydapt · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing